Abstracts tagged "Lupus"

Abstract Number: 712 • 2014 ACR/ARHP Annual Meeting
Mapping the Disease-Specific Lupusqol to the SF-6D
Rachel Meacock¹, Mark Harrison², Kathleen McElhone³, Janice Abbott⁴, Sahena Haque⁵, Ian N. Bruce⁶ and Lee- Suan Teh⁷, ¹Centre for Health Economics, The University of Manchester, Manchester, United Kingdom, ²University of British Columbia, Vancouver, BC, Canada, ³Royal Blackburn Hospital, Blackburn, United Kingdom, ⁴University of Central Lancashire, Preston, United Kingdom, ⁵University Hospital of South Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁷Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom
Background/Purpose: The LupusQoL is a measure of health-related quality of life (HRQoL) developed specifically to assess the impact of systemic lupus erythematosus (SLE) and its…
Abstract Number: 637 • 2014 ACR/ARHP Annual Meeting
Decreased Inflammatory Dendritic Cells in Lupus-Prone Estrogen Receptor Alpha Knockout (ERαKO) Mice Correlate with Increased Survival
Melissa A. Cunningham¹, Jena R. Wirth², Jackie G. Eudaly³, Jennifer L. Scott⁴, Osama S. Naga³ and Gary S. Gilkeson⁵, ¹Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ²Med/Rheumatology, MUSC, Charleston, SC, ³Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: SLE is a disease that disproportionately affects females. The etiology of the sex bias in this disease is unclear. We previously showed that a…
Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Sascha Tillmanns¹, Claudia Kolligs¹, David P. D'Cruz², Andrea Doria³, Eric Hachulla⁴, Reinhard E. Voll⁵, Michael Tansey¹ and Klaus Schollmeier⁶, ¹Medical/Clinical, SuppreMol GmbH, Martinsried, Germany, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ³Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁴Medicine Interne et Oncologie Medicale Centre Pole, Lille University, Lille, France, ⁵Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany, ⁶SuppreMol GmbH, Martinsried, Germany
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…
Abstract Number: 1643 • 2014 ACR/ARHP Annual Meeting
Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated?
Rodolfo Perez Alamino¹, Raquel Cuchacovich², Arnold Zea³ and Luis R. Espinoza⁴, ¹internal Medicine, LSUHSC, New Orleans, LA, ²Rheumatology, LSU Medical Center, New Orleans, LA, ³Stanley Scott Cancer Center, New Orleans, LA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA
Background/Purpose Systemic lupus erythematosus (SLE) presents with a wide spectrum of clinical and immunologic abnormalities. On the other hand, exciting data is emerging about the…
Abstract Number: 707 • 2014 ACR/ARHP Annual Meeting
Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody
Samera Vaseer¹, Judith A. James², Aikaterini Thanou³ and Joan T. Merrill⁴, ¹Rheumatology, University Of Oklahoma, Oklahoma City, OK, ²Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Pulmonary involvement is frequent in systemic lupus erythematosus (SLE) and can affect the pleura, pulmonary vasculature, and parenchyma. The prevalence of ILD is lower…
Abstract Number: 485 • 2014 ACR/ARHP Annual Meeting
Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment – a Two-Year Prospective Study in an Interdisciplinary Patient Cohort
Simon Julius Winkelmann¹, Rainald A. Zeuner¹, Dörte Schuldt¹, Johannes Bethge¹, Ulrich Mrowietz², Matthias Laudes¹, Stefan Schreiber¹ and Johann Schroeder¹, ¹1st Medical Dept, University of Kiel, Kiel, Germany, ²Dermatology, Univ Schleswig-Holstein, Kiel, Germany
Background/Purpose: TNFα-Inhibitors are the most widely used biological agents in rheumatic conditions or other chronic inflammatory diseases. Over the last ten years, the occurrence of…
Abstract Number: 2736 • 2014 ACR/ARHP Annual Meeting
Female Specific Increase in T Cell Glycosylation in Lupus
Gabriela Gorelik¹ and Bruce Richardson², ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease characterized by altered T cell signaling. SLE is characterized by epigenetic mechanisms that cause hypomethylation…
Abstract Number: 1629 • 2014 ACR/ARHP Annual Meeting
Added Value of the Determination of Anti-Ribosomal and Anti-Ku Antibodies for Diagnosis of Systemic Lupus Erythematosus
Johannes Schulte-Pelkum¹, Diana Carmona-Fernandes², Maria Jose Santos², Roger Albesa¹ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Background/Purpose Anti-dsDNA antibodies (aab) are known as important serological marker to aid in the diagnosis of systemic lupus erythematosus (SLE) and are part of the…
Abstract Number: 698 • 2014 ACR/ARHP Annual Meeting
Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus
James S. Andrews¹, Mary Margaretten², Jennifer Barton², Jinoos Yazdany², Ed Yelin² and Patricia P. Katz³, ¹Rheumatology, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, CA
Background/Purpose: Muscle weakness is common and contributes to physical disability in women with systemic lupus erythematosus (SLE). Recently, the Foundation for the National Institutes of…
Abstract Number: 77 • 2014 ACR/ARHP Annual Meeting
Epigenome Profiling Reveals Robust Hypomethylation of Interferon Signature Genes in Lupus Neutrophils
Patrick Coit¹, Sri Yalavarthi¹, Wenpu Zhao², Mariana J. Kaplan² and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Lupus neutrophils play an important role in tissue damage (including glomerulonephritis and lupus skin involvement), as well as endothelial damage in lupus patients. Several…
Abstract Number: 2741 • 2014 ACR/ARHP Annual Meeting
The Role of Fli1 in Lupus T Cell Function and Nephritis
Thirumagal Thiyagarajan¹, Ivan Molano² and Tamara K. Nowling³, ¹Medicine, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ³Medicine/Rheumatology, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC
Background/Purpose: The Ets factor Fli1 is implicated as a key modulator of lupus disease expression. Over-expressing Fli1 in healthy mice, results in the development of…
Abstract Number: 1625 • 2014 ACR/ARHP Annual Meeting
Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles
Kimberly Carroll¹, Elizabeth Mitton-Fitzgerald¹, Brittany Bettendorf², Claudia Gohr¹, Mary E. Cronin¹ and Ann K. Rosenthal³, ¹Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Internal Medicine/Pediatrics, Medical College of Wisconsin, Wauwatosa, WI, ³Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Microparticles (MPs) are circulating membrane-bound vesicles derived from blood and endothelial cells via a highly regulated process. They are immunomodulatory and have been implicated…
Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting
Corticosteroids in Early Treatment Pathways in SLE
John G. Hanly¹, Amyn Sayani², Steve Doucette³, Sandra Iczkovitz² and Jorge Alfonso Ross², ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ³Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…
Abstract Number: L23 • 2014 ACR/ARHP Annual Meeting
Humoral Immune Response to Pneumococcal Polysaccharide Vaccine in SLE Patients on Immunosuppressive Therapy: Assessment of Serotypes without Protective Antibody Levels
Rodrigo Poubel V. Rezende¹, Francinne M. Ribeiro¹, Luis Eduardo C. Andrade², Carlos Roberto M. Gayer³, Elisa M. N. Albuquerque¹ and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Fleury Laboratories, Sao Paulo, Brazil, ³Department of Biochemistry, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose: Previous works assessing antibody response to pneumococcal polysaccharide vaccine (PPV) in systemic lupus erythematosus (SLE) relied exclusively on the quantitative increase in antibody titers…
Abstract Number: 2676 • 2014 ACR/ARHP Annual Meeting
The E3 Ligase Casitas B Lineage Lymphoma b (Cbl-b) Modulates Peripheral Regulatory T Cell Function Via p27^kip1in Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín¹, Jorge Romo-Tena², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The interplay between effector and regulatory T cells (Tregs) is a key element among peripheral tolerance mechanisms in Systemic Lupus Erythematosus (SLE). Resistance to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].